Genzyme asks FDA to expand clofarabine's use to adults

11/24/2008 | American City Business Journals

Genzyme submitted an application seeking FDA approval to market clofarabine to treat adults with acute myeloid leukemia. The biotech firm already sells the drug under the brand Clolar for relapsed and treatment-resistant patients between ages 1 and 21 who suffer from acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC